Page 142 - Drug Class Review

Page 101 of 205
Drug Effectiveness Review Project

placebo 75.3 64.5 89.4% 4.6% 6.0% 17.1 Clinically evident functional decline, defined as any of the following: Decline > 1 point on ADFACS basic ADLs present at baseline, except that a decline from 0 (no impairment) to 1 (mild impairment) was not considered clinically significant Decline in ability to perform 20% or more of ADFAC instrumental ADLs; a decline from 0 (no impairment) to 1 (mild impairment) was not considered clinically significant but other declines Increase in global CDR score > 1 point compared to baseline Timing of assessments: Baseline and

Alzheimer classification: Mild-moderate

Groups similar at baseline: Yes

donepezil 75.4 61.3 94.9% 0.9% 4.2% 17.1 Primary Outcome Measures: ADFACS; CDR of one or more were Secondary Outcome Measures: ADL; CDR; MMSE Health Outcome Measures: days) compared to DON (357 days)*

1) 2) 3) • • •

Final Report Update 1 Authors: Mohs et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: Baseline MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs